Low-dose dopamine does not affect renal function in cytarabine-administered patients
Variations exist among patients who received low-dose dopamine, but overall use of the said drug does not have a significant impact on renal function, according to a study. In addition, low-dose dopamine shows no adverse effect on cardiovascular (CV) function.
Researchers performed a retrospective, single-centre, cohort study of patients receiving cytarabine at 667 mg/m2/dose or greater, with or without dopamine at ≤5 mcg/kg/min, to evaluate changes in renal function, CV adverse events and neurologic toxicity in these individuals. Cohorts were based upon initiation or absence of low-dose dopamine: cytarabine only, cytarabine + pre- and day of low-dose dopamine, and cytarabine + post-low-dose dopamine.
Researchers compared renal outcomes (urine output, serum creatinine and creatinine clearance) with baseline and between cohorts. Safety endpoints (arrhythmias, tachycardia and neurotoxicity) were also compared between cohorts based on exposure to low-dose dopamine.
No difference was observed in urine output from baseline in all cohorts. There was no difference in urine output between cytarabine only and pre- and day of low-dose dopamine cohorts. Also, serum creatinine and creatinine clearance were not different from baseline among patients receiving low-dose dopamine.
During the study period, there were arrhythmias recorded, and there was no between-group difference in the incidence of tachycardia (p=0.06). Three patients administered low-dose dopamine had neurotoxicity.
“Low-dose dopamine has been utilized to improve renal blood flow, urine output and reduce drug-induced nephrotoxicity,” researchers noted.
A meta-analysis by Friedrich and colleagues found that low-dose dopamine provided transient improvement in renal physiology. However, there was no good evidence showing that it offers significant clinical benefits to patients with or at risk for acute renal failure. [Ann Intern Med 2005;142:510-24]